Results 141 to 150 of about 2,385 (197)
Platelet Inhibition with Cangrelor [PDF]
New England Journal of Medicine, 2010 Platelet inhibition with cangrelor.
Neil, Ruparelia, Nicos, Spyrou
core +6 more sources
Use of Cangrelor in Older Patients: Findings from the itAlian pRospective Study on CANGrELOr Study [PDF]
The American Journal of CardiologyOutcome data on using cangrelor in older patients are limited. This post hoc analysis of the itAlian pRospective Study on CANGrELOr (ARCANGELO) study aims to assess bleeding and ischemic outcomes with the transition from cangrelor to any oral P2Y12 inhibitors in age-stratified subgroups (≥75 years-older,
Capranzano, Piera +13 more
openaire +4 more sources
Clinical use of cangrelor: nationwide experience from the Swedish Coronary Angiography and Angioplasty Registry (SCAAR) [PDF]
European Heart Journal - Cardiovascular Pharmacotherapy, 2019 AIMS: This nationwide study aimed to analyse the first 2 years of routine clinical use of cangrelor in all Swedish patients undergoing percutaneous coronary intervention (PCI).
Per Grimfjärd +2 more
exaly +2 more sources
Some of the next articles are maybe not open access.
Related searches:
Related searches:
Future Cardiology, 2020
Inadequate antiplatelet effects can result in substantial morbidity and mortality in patients with acute coronary syndrome and percutaneous coronary intervention (PCI). Cangrelor is a rapid onset and potent intravenous P2Y12 inhibitor that has been shown in large randomized controlled trials to reduce periprocedural complications for PCI compared with ...
Kent Y, Feng, Kenneth W, Mahaffey
openaire +2 more sources
Inadequate antiplatelet effects can result in substantial morbidity and mortality in patients with acute coronary syndrome and percutaneous coronary intervention (PCI). Cangrelor is a rapid onset and potent intravenous P2Y12 inhibitor that has been shown in large randomized controlled trials to reduce periprocedural complications for PCI compared with ...
Kent Y, Feng, Kenneth W, Mahaffey
openaire +2 more sources
Pharmacodynamic Effects of Cangrelor on Platelet P2Y12 Receptor–Mediated Signaling in Prasugrel-Treated Patients [PDF]
JACC: Cardiovascular Interventions, 2014 ObjectivesThe purpose of this study was to assess the in vitro P2Y12 receptor inhibitory effects of cangrelor on platelets from patients on maintenance prasugrel therapy treated with 2 reloading dose regimens.BackgroundDespite its more potent and rapid ...
Fabiana Rollini +2 more
exaly +2 more sources
The Use of Cangrelor in Cardiogenic Shock: Insights from the CAMEO Registry [PDF]
Journal of Cardiac FailureINTRODUCTION: Little is known about the use of cangrelor in patients with myocardial infarction (MI) presenting with cardiogenic shock (CS). METHODS: CAMEO (Cangrelor in Acute MI: Effectiveness and Outcomes) is a multicenter observational registry ...
Courtney Page, Mir B Basir
exaly +1 more source